secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0000950170-25-094588
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight preliminary Q2 revenue $33.6M, down 4% YoY; cuts FY2025 guidance to $120-130M
--------------------------------------------------------------------------------

- Preliminary Q2 revenue ~$33.6M, down 4% YoY and 11% sequentially; LAL volume +13% YoY, LDD sales -49% YoY.
- FY2025 revenue guidance slashed to $120-130M (from $160-175M), implying 7-14% decrease from 2024.
- Gross margin guidance raised to 72-74% (from 71-73%); operating expense guidance $145-155M, up 7-14% YoY.
- Installed LDD base of 1,084 units (+34% YoY); management cites underperformance and plans to refocus commercial strategy.
- Cash $227.5M as of June 30, 2025, down $1.8M from March 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017025094588/0000950170-25-094588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017025094588/rxst-20250708.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-094588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer